The funnel discount versus the specialist premium: mass-market telehealth against board-certified obesity medicine on membership.
The two models
Hims is the category’s marketing heavyweight with its most contested model: after its Novo Nordisk partnership collapsed in June 2025, it leaned into “personalized” compounded semaglutide — the legal rationale regulators and manufacturers dispute most directly. Advertised entry prices are aggressive; true maintenance-dose totals are exactly what our pending verification exists to establish.
Mochi Health is the obesity-medicine specialist play: board-certified obesity clinicians on a membership model, with medication costs separate. It’s the structural bet that care depth — titration judgment, comorbidity management — is worth paying for distinctly. Membership-plus-medication totals are queued for verification.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Who is actually treating you
The comparison compresses to one intake question: who adjusts your dose when week nine goes sideways — a protocol, or a specialist who treats obesity all day? Complexity (comorbidities, medication stacks, prior GI history) argues for the clinical depth Mochi sells; simplicity argues you may not need to pay for it. Neither’s totals are verified; the structural trade is real either way.
Go deeper
Full files: Hims · Mochi Health. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.